Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $12.9 billion.

  • Genmab A's Liabilities and Shareholders Equity rose 10070.16% to $12.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $32.9 billion, marking a year-over-year increase of 8391.11%. This contributed to the annual value of $12.9 billion for FY2025, which is 10070.16% up from last year.
  • Per Genmab A's latest filing, its Liabilities and Shareholders Equity stood at $12.9 billion for Q4 2025, which was up 10070.16% from $7.0 billion recorded in Q3 2025.
  • Genmab A's Liabilities and Shareholders Equity's 5-year high stood at $12.9 billion during Q4 2025, with a 5-year trough of $5.2 billion in Q4 2023.
  • In the last 3 years, Genmab A's Liabilities and Shareholders Equity had a median value of $6.4 billion in 2024 and averaged $7.0 billion.
  • Data for Genmab A's Liabilities and Shareholders Equity shows a peak YoY increase of 10070.16% (in 2025) and a maximum YoY decrease of 1659.45% (in 2025) over the last 5 years.
  • Genmab A's Liabilities and Shareholders Equity (Quarter) stood at $5.2 billion in 2023, then rose by 22.59% to $6.4 billion in 2024, then surged by 100.7% to $12.9 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $12.9 billion for Q4 2025, versus $7.0 billion for Q3 2025 and $6.5 billion for Q2 2025.